Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 30:14:3651-3663.
doi: 10.2147/JPR.S326101. eCollection 2021.

A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders

Affiliations
Review

A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders

Giovanni Iolascon et al. J Pain Res. .

Abstract

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. Although there are some differences in the authorized indications between countries, aceclofenac is mainly recommended for the treatment of inflammatory and painful processes, such as low back pain (LBP), scapulohumeral periarthritis, extraarticular rheumatism, odontalgia, and osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). The analgesic properties and tolerability profile of aceclofenac in musculoskeletal disorders are reviewed, focusing on relevant and recent studies. The efficacy and safety comparison of aceclofenac with other analgesics and anti-inflammatory agents in OA, AS, RA, and LBP is described. Relevant studies were identified following a literature search of PubMed using the terms "aceclofenac" and "clinical trials" published from 1 Jan 1992 to 1 Jan 2020. Aceclofenac is at least as effective as other NSAIDs in reducing pain and/or improving functional capacity in chronic pain conditions (OA, AS, RA, and LBP). It is generally well tolerated and appears to have a more favorable GI profile than other NSAIDs. Thus, current evidence indicates that aceclofenac is a useful option for the management of pain and inflammation across a wide range of painful conditions.

Keywords: NSAIDs; aceclofenac; analgesia; low back pain; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in relation to this article.

Figures

Figure 1
Figure 1
Tolerability of aceclofenac versus naproxen (A and B), piroxicam (C), indomethacin (D) and ketoprofen (E) in clinical studies. p values reported where available.
Figure 2
Figure 2
The pooled relative risk (RR) of upper gastrointestinal complications with the use of NSAIDs versus non-use of NSAIDs according to a systematic review and meta-analysis of observational studies. Vertical bars represent 95% confidence intervals. Of note, rofecoxib has been withdrawn from the market due to cardiovascular adverse events. Republished from Springer Nature, Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–1146; permission conveyed through Copyright Clearance Center, Inc.

Similar articles

Cited by

References

    1. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351–1378. doi:10.2165/00003495-200161090-00012 - DOI - PubMed
    1. Brogden RN, Wiseman LR. Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs. 1996;52(1):113–124. doi:10.2165/00003495-199652010-00008 - DOI - PubMed
    1. Almirall Ltd. PRESERVEX® (aceclofenac) 100 mg film-coated tablets: UK summary of prescribing characteristics; 2018. Available from: https://www.medicines.org.uk/emc/product/6578/smpc. Accessed November 6, 2021.
    1. Almirall SA. Airtal (aceclofenac) 100 mg film-coated tablets: summary of product characteristics; 2014. Available from: https://cima.aemps.es/cima/dochtml/ft/59024/FT_59024.html. Accessed November 6, 2021.
    1. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000. doi:10.1161/ATVBAHA.110.207449 - DOI - PMC - PubMed